SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

BRIEF-Celcuity Says Breast Cancer Clinical Trial Collaboration With MD Anderson, Novartis, And Puma Biotechnology To Study New Drug Regimen

· 03/16/2021 16:04
BRIEF-Celcuity Says Breast Cancer Clinical Trial Collaboration With MD Anderson, Novartis, And Puma Biotechnology To Study New Drug Regimen

- Celcuity Inc CELC.O:

  • CELCUITY ANNOUNCES BREAST CANCER CLINICAL TRIAL COLLABORATION WITH MD ANDERSON, NOVARTIS, AND PUMA BIOTECHNOLOGY TO STUDY NEW DRUG REGIMEN

  • CELCUITY INC - FIVE CLINICAL TRIAL COLLABORATIONS ARE NOW IN PLACE AND INCLUDE ONES WITH GENENTECH, PFIZER, NOVARTIS AND PUMA

  • CELCUITY INC - EXPECTS ENROLLMENT TO BEGIN IN Q2 OF 2021

  • CELCUITY INC - TRIAL WILL EVALUATE EFFICACY AND SAFETY OF NOVARTIS' TARGETED THERAPY TABRECTA AND PUMA'S NERLYNX

Source text for Eikon: ID:nBw5qvpTKa

Further company coverage: CELC.O


((Reuters.Briefs@thomsonreuters.com;))